Oncolytics Biotech Inc T.ONC

05 September new RioGlio/ Pelareorep Article

[askretka]

https://academic.oup.com/neuro-oncology/article/24/Supplement_2/ii73/6692053 ------------------------------------- Another good article by Oncology virus expert Alan Melcher. Cheers!!!!!!

[Noteable]

" In this RepGlio study the 24-month survival estimate for all patients was 25.0%, 16.7% for dose level 1 and 33.3% for dose level 2."  By comparison in a 2018 retrosepctive GBM study in a patient population of seventy-seven patients who were treated by multimodality therapy such as surgery plus post-operative radiotherapy (PORT), post-operative Temozolomide (TMZ) concurrent with

[Noteable]

In this ONCY ReoGlio study of newly diagnosed GBM patients, none of the 15 ReoGlio patients underwent debilitating surgery nor did they require followup chemoradiotherapy, whereas in the the 2018 retrospective study of 77 patients, all patients underwent surgery, as well as 2 courses of chemoradiotherapy (TMZ+ post-operative radiotherapy). 

[Capitalista]

Thanks for the comparative data, Noteable.  This was not presented in Short et al's abstract (might have been in the article itself?) and was needed to put their results in context.  

[Noteable]

The comparative data is separate to the following Short et al. study abstract. which I provided it to show some further context to the results presented by the ReoGlio investigators. .A. LONG-TERM FOLLOW UP AND TRANSLATIONAL DATA FROM THE REOGLIO PHASE IB TRIAL OF GM-CSF AND INTRAVENOUS PELAREOREP (REOVIRUS) ALONGSIDE STANDARD OF CARE IN GBM S. Short1, J. Kendall1, E. West1, A